Calcitriol in the treatment of postmenopausal osteoporosis

Aloia, John F.; Vaswani, A.; Yeh, James K.; Ellis, Kenneth; Yasumura, S; Cohn, S. H.

doi:10.1016/0002-9343(88)90259-8

Cited by 206 publications

(89 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…64,118,120,123 In three studies, vertebral fracture was a secondary outcome measure 63,119,133 and in two, in which vertebral fracture was included as an outcome measure, there was no apparent differentiation between primary and secondary outcome measures. 117,121 Non-vertebral fractures were a secondary outcome measure in three studies, 63,122,123 and were mentioned in a further study that did not appear to differentiate between primary and secondary outcome measures. 121 In only five studies were effects on vertebral fractures reported as the numbers of patients in each arm sustaining fractures.…”

Section: Vitamin D Derivativesmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.This has meant that the HTA panels can now focus more explicitly on health technologies ('health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care) rather than settings of care. Therefore the panel structure has been redefined and replaced by three new panels: Pharmaceuticals; Therapeutic Procedures (including devices and operations); and Diagnostic Technologies and Screening.The HTA Programme continues to commission both primary and secondary research. The HTA Commissioning Board, supported by the National Coordinating Centre for Health Technology Assessment (NCCHTA), will consider...

show abstract

Section: Vitamin D Derivativesmentioning

confidence: 99%

“…63,64,[117][118][119][120][121][122][123] These trials included those in which patients in both the intervention and control groups received calcium and/or vitamin D in comparable doses. Those studies in which vitamin D derivatives were compared with another active intervention are discussed later (page 36).…”

Section: Vitamin D Derivativesmentioning

confidence: 99%

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Kanis

Brazier

Stevenson

et al. 2002

Health Technol Assess

207

View full text Add to dashboard Cite

show abstract

“…These results may indicate that 1a(OH)D3 has a suppressive effect on In earlier studies, a decrease in excretion following active vitamin D analogue was reported [6][7][8][9][10]. In ovariectomized animals, the inhibitory effect of 1, 25 (OH)2D3 on bone resorption has been demonstrated [3,4].…”

Section: Discussionmentioning

confidence: 66%

“…Taking into account the fact that the loss of L2-4 BMD measured by DXA was as much as 8% per year as demonstrated in the control group of the preventive trial, L2-4 BMD measured by DXA is a good endpoint for the evaluation of the agent in early menopausal subjects. The endpoints used in other studies in the literature are L2.4 BMD as measured by dual photon absorptiometry [6][7][8]12] and the incidence of fractures [7,8,12,13]. The percent change in these parameters was not more than 5% in one year, because the subjects studied were more than 60 years old.…”

Section: Discussionmentioning

confidence: 99%

Effect of 1 .ALPHA.-Hydroxyvitamin D3 on Loss of Bone Mineral Density Immediately after Artificial Menopause.

et al. 1997

View full text Add to dashboard Cite

Abstract.To evaluate the effects of 1a-hydroxyvitamin D3 (la(OH)D3), a series of clinical trials, preventive and therapeutic, were performed in an open label manner in women immediately after oophorectomy. The series included a total of 121 oophorectomized subjects, whose lumbar bone mineral density (L2~BMD) was followed by the use of dual energy X-ray absorptiometry.(1) Preventive trial: 61 women who had undergone premenopausal bilateral oophorectomy, were divided into 3 groups (Group C: control; Group L: 0.254ug 1a(OH)D3/day; Group H: 0.50-0.75µg 1a(OH)D3/day).The changes in BMD and chemical indices were followed up for one year. (2) Therapeutic trial: the trial included 60 premenopausally oophorectomized subjects having L2IBMD lower than the normal control level minus 1SD which has been reported in age-matched normal Japanese women. These subjects were divided into 3 groups and treated in the same way as in the preventive trial. In the preventive trial, L2~BMD decreased by 8.2%, 6.5% and 4.5% in groups C, L and H, respectively, at 12 months of treatment, whereas in the therapeutic trial, L2.4BMD decreased by 3.6%, 3.2% and 0.8% in the groups C, L and H, respectively, at 12 months of treatment. In conclusion, la(OH)D3 was found to be effective both to prevent the bone loss subsequent to bilateral oophorectomy and improve low bone mass after oophorectomy.

show abstract

“…Vitamin D metabolites have proved to be effective in preventing osteoporosis by increasing low mineral density [2] and decreasing fracture rates [3][4][5] while showing a low toxicity; the incidence of hypercalcemia is <1 % [6]. The prevention of bone loss has been shown to be due to restoration to a positive calcium balance due to a correction of calcium malabsorption [7].…”

mentioning

confidence: 99%

Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites?

Kranich

Schacht³

et al. 1997

Calcif Tissue Int

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate whether fast trabecular bone loss in osteoporotic and osteopenic patients can effectively be treated with active vitamin D metabolites. Thirty-one osteoporotic and osteopenic patients were monitored between 4 and 22 months before and between 8 and 18 months during the treatment. Fast bone losers were designated as osteoporotic or osteopenic patients with a loss of trabecular bone density in the radius of 3% or more calculated for 1 year. For this differentiation, the high precise peripheral quantitative computed tomography system (DENSISCAN 1000) was used (reproducability 0.3% in mixed collectives). The pretreatment loss and the "gain" under treatment with active vitamin D metabolites was calculated for 1 year. The treatment consisted of either 0.5 flg calcitriol daily or 1 flg of alfacalcidol daily. Before treatment, the trabecular bone loss in the radius/year was -6.6 ± 0.5% (mean ± SEM). After treatment with vitamin D metabolites, the trabecular bone gain in the radius/year was 0.01 ± 0.6% (mean ± SEM). The difference was highly significant (P < 0.001). In contrast to this, the loss of cortical bone density before treatment was -1.8 ± 0.3% (mean ± SEM) and the reduced loss after treatment -0.2 ± 0.4% (mean ± SEM), both values calculated for I year. This difference was less significant (P < 0.05). This study shows that the treatment with active vitamin D metabolites is very effective in slowing fast trabecular bone loss in osteoporotic and osteopenic patients.Key words: Fast bone loss -Osteoporosis -Quantitative computed tomography -Calcitriol -Alfacalcidol.In postmenopausal and senile osteoporosis, reduced calcium absorption is often reported. Pathophysiologically, a disorder in the vitamin D metabolism as cause can be postulated, although it is of a different character. For both groups a lower concentration of 1,25(OHhD 3 in the serum, a decrease of the amount of 1,25(OHhD3 receptors, and a disorder of the active calcium absorption in the intestine is known. For the postmenopausal osteoporosis there is a low parathyroid hormone (PTH) level and an additional deficit in the activation of the PTH-induced 1,25(OHhD3 synthesis. For the senile osteoporosis, in addition to the above, there is a lack of vitamin D uptake and an increase in the Vitamin D metabolites have proved to be effective in preventing osteoporosis by increasing low mineral density [2] and decreasing fracture rates [3][4][5] while showing a low toxicity; the incidence of hypercalcemia is <1 % [6]. The prevention of bone loss has been shown to be due to restoration to a positive calcium balance due to a correction of calcium malabsorption [7]. Furthermore, it has been reported that treatment with alfacalcidol improves the myopathy associated with the bone loss of aging [8] and should reduce the tendency to fall and the risk of osteoporotic fractures.Until now anabolic substances like fluorides were used for the tailored treatment of osteoporosis in slow bone losers (loss of trabecular bone density in...

show abstract

Calcitriol in the treatment of postmenopausal osteoporosis

Cited by 206 publications

References 16 publications

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Treatment of established osteoporosis: a systematic review and cost-utility analysis

Effect of 1 .ALPHA.-Hydroxyvitamin D3 on Loss of Bone Mineral Density Immediately after Artificial Menopause.

Can the fast bone loss in osteoporotic and osteopenic patients be stopped with active vitamin D metabolites?

Contact Info

Product

Resources

About